Creo Medical Group plc announced that, following a recent submission to the Company's notified body, Creo have been advised on a regulatory pathway facilitating the launch of their Speedboat UltraSlim device approximately 18 months ahead of schedule. This news will now enable the Company to initiate the launch of UltraSlim in Europe in early 2024, with an early adopter launch programme which would otherwise have been planned for mid-2025. Speedboat UltraSlim is the second brand in its Speedboat family of devices alongside Speedboat Inject and offers a number of different features.

The primary feature is the reduced size in comparison with the Speedboat Inject, making the device compatible with all endoscopes with a 2.8mm working channel or larger, accounting for the vast majority of GI endoscopic procedures, and significantly increasing the opportunity for more clinicians and patients to benefit from Creo's game-changing technology. The UltraSlim device is targeting the therapeutic treatment of Gastrointestinal ("GI") tract lesions (including Bowel and Upper GI cancers, and pre-cancerous lesions) and swallowing disorders. Powered by Creo's CROMA advanced energy platform, the UltraSlim delivers advanced bi-polar Radiofrequency ("RF") energy for controlled cutting and high frequency microwave ("MW") energy for controlled coagulation of tissue in the GI tract.

UltraSlim's injection functionality is achieved through an integrated lifting system.